Fetuin-A – Alpha2-Heremans-Schmid Glycoprotein: From Structure to a Novel Marker of Chronic Diseases Part 2. Fetuin-A – A Marker of Insulin Resistance and Related Chronic Diseases

1. Mori K, Emoto M, Inaba M. Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discov. 2011;5(2):124–46.10.2174/187221411799015372Search in Google Scholar

2. Hermans JF. Les Globuline, Sériques du Système Gamma. Masson et Cie, editor. Paris: Arscia-Bruxelles; 1960.Search in Google Scholar

3. Schmid K, Burgi W. Preparation and properties of the human Ba-a2 glycoproteins. Biochim Biophys Acta. 1961;47:440-3.10.1016/0006-3002(61)90539-XSearch in Google Scholar

4. Pedersen KO. Fetuin, a new globulin isolated from serum. Nature. 1944; 154:575.10.1038/154575a0Search in Google Scholar

5. Gejyo, F, Schmid K. Purification and characterization of the two forms of human plasma α₂ HS-glycoprotein. Biochim Biophys Acta. 1981; 671(1):78-84.10.1016/0005-2795(81)90096-9Search in Google Scholar

6. Kübler D, Gosenca D, Wind M, Heid H, Friedberg I, Jahnen-Dechent W, et al. Proteolytic processing by matrix metalloproteinases and phosphorylation by protein kinase CK2 of fetuin-A, the major globulin of fetal calf serum. Biochimie. 2007;89(3):410-8.10.1016/j.biochi.2006.10.012Search in Google Scholar

7. Bendiak B, Harris-Brandts M, Michnick SW, Carver JP, Cumming DA. Separation of the complex asparagine-linked oligosaccharides of the glycoprotein fetuin and elucidation of three triantennary structures having sialic acids linked only to galactose residues. Biochemistry.1989;28(15):6491-9.10.1021/bi00441a050Search in Google Scholar

8. Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y. Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem. 1997; 243(3):753-61.10.1111/j.1432-1033.1997.00753.xSearch in Google Scholar

9. Haglund AC, Ek B, Ek P. Phosphorylation of human plasma alpha2-Heremans-Schmid glycoprotein (human fetuin) in vivo. Biochem J. 2001;357(2):437-45.10.1042/bj3570437Search in Google Scholar

10. Hortin GL, Schilling M, Graham JP. Inhibitors of the sulfation of proteins, glycoproteins, and proteoglycans. Biochem Biophys Res Commun.1988;150(1):342-8.10.1016/0006-291X(88)90526-8Search in Google Scholar

11. Naseem F, Khan RH, Haq SK, Naeem A. Characterization of molten globule state of fetuin at low pH. Biochim Biophys Acta. 2003;1649(2):16-70.10.1016/S1570-9639(03)00169-9Search in Google Scholar

12. Guttman M, Weinkam P,2 Sali A, Lee KK. All-atom ensemble modeling to analyze small-angle x-ray scattering of glycosylated proteins. Structure. 2013; 21(2):321-31.10.1016/j.str.2013.02.004Search in Google Scholar

13. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell.1989;58(4):631-40.10.1016/0092-8674(89)90098-6Search in Google Scholar

14. Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol. 2000;164(1-2):87-98.10.1016/S0303-7207(00)00237-9Search in Google Scholar

15. Brown WM, Dziegielewska KM, Saunders’ NR, Christie DL, Nawratil P, Muller-Esterl W. The nucleotide and deduced amino acid structures of sheep and pig fetuin. Common structural features of the mammalian fetuin family. Eur J Biochem. 1992;205(1):321-31.10.1111/j.1432-1033.1992.tb16783.x1372866Search in Google Scholar

16. Dziegielewska K, Brown WM, Deal, A, Foster KA, Fry EJ, Saunders NR. The expression of fetuin in the development and maturation of the hemopoietic and immune systems. Histochem Cell Biol. 1996;106(3):319-30.10.1007/BF024732428897073Search in Google Scholar

17. Carvalho BM, Abdalla Saad MJ. Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediators Inflamm. 2013;1-13.10.1155/2013/986734369452723840101Search in Google Scholar

18. Cintrón VJ, Ko MS, Chi KD, Gross JP, Srinivas PR, Goustin AS, et al. Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: the mouse ortholog of human alpha2-HS glycoprotein. Int J Exp Diabetes Res. 2001;1(4):249-63.10.1155/EDR.2000.249247774311467416Search in Google Scholar

19. Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun. 2006;350(2):437-43.10.1016/j.bbrc.2006.09.07117011519Search in Google Scholar

20. Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(3):352-9.10.5507/bp.2015.01825916279Search in Google Scholar

21. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006;113(14):1760-7.10.1161/CIRCULATIONAHA.105.588723277666916567568Search in Google Scholar

22. Taylor R. Insulin resistance and type 2 diabetes. Diabetes. 2012; 61(4):778-9.10.2337/db12-0073331434622442298Search in Google Scholar

23. Goustin AS, Derar N,.Abou-Samra AB. Ahsgfetuin blocks the metabolic arm of insulin action through its interaction with the 95-kD β-subunit of the insulin receptor. Cell Signal. 2013;25(4):981-8.10.1016/j.cellsig.2012.12.01123314177Search in Google Scholar

24. Goustin A-S. Human Ahsg (fetuin-A) mature protein (model in PyMol) [Internet]. 2012 Jun [cited 2018 Jun 10]. Available from: https://www.youtube.com/watch?v=C212S_owySwSearch in Google Scholar

25. WHO. Global report on diabetes [Internet]. 2016 [cited 2018 Jun 10]. Available from:http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=B0D9E4564FCBF06628ABAC20F1CC29D6?sequence=1Search in Google Scholar

26. Jacobs S, Kröger J, Floegel A, Boeing H, Drogan D, Pischon T, et al. Evaluation of various biomarkers as potential mediators of the association between coffee consumption and incident type 2 diabetes in the EPIC-Potsdam Study..Am J Clin Nutr. 2014;100(3):891-900.10.3945/ajcn.113.08031725057154Search in Google Scholar

27. Lorant DP, Grujicic M, Hoebaus C, Brix JM, Hoellerl F, Schernthaner G, et al. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2011;34(1):156-61.10.2337/dc10-0788300544620929991Search in Google Scholar

28. Norbert S, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008;57(10):2762-7.10.2337/db08-0538255168718633113Search in Google Scholar

29. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin.Endocrinol Metab. 2008;93(11):4479-85.10.1210/jc.2008-150518728159Search in Google Scholar

30. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F. A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes. 2005;54(8):2477-81.10.2337/diabetes.54.8.247716046317Search in Google Scholar

31. Sindhu S, Akhter N, Shenouda S, Wilson A, Ahmad R. Plasma fetuin-A/α2-HS-glycoprotein correlates negatively with inflammatory cytokines, chemokines and activation biomarkers in individuals with type-2 diabetes. BMC Immunol. 2016;17:33.10.1186/s12865-016-0171-y503763727671862Search in Google Scholar

32. Li W, Zhu S, Li J, Huang Y, Zhou R, Fan X, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One. 2011;6(2):e16945.10.1371/journal.pone.0016945303567521347455Search in Google Scholar

33. Guo VY, Cao B, Cai C, Cheng KK, Cheung BMY. Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol. 2018;55(1):87-98.10.1007/s00592-017-1068-929127490Search in Google Scholar

34. Roshanzamir F, Miraghajani M, Rouhani MH, Mansourian M, Ghiasvand R, Safavi SM. The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies.. J Endocrinol Invest. 2018;41(1):33-47.10.1007/s40618-017-0697-828643299Search in Google Scholar

35. Erdmann J, Salmhofer H, Knauß A, Mayr M, Wagenpfeil S, Sypchenko O, et al. Relationship of fetuin-A levels to weight-dependent insulin resistance and type 2 diabetes mellitus. Regul Pept. 2012;178(1-3):6-10.10.1016/j.regpep.2012.02.00422387701Search in Google Scholar

36. Ismail NA, Ragab S, Abd El Dayem SM, ElBaky AA, Salah N, Hamed M, et al. Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch Med Sci. 2012;8(5):826-33.10.5114/aoms.2012.31616350623823185191Search in Google Scholar

37. Xu Y, Xu M, Bi Y, Song A, Huang Y, Liu Y, et al. Serum fetuin-A is corretaled with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis. 2011;216(1):180-6.10.1016/j.atherosclerosis.2011.01.02021310413Search in Google Scholar

38. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115(19):2533-9.10.1161/CIRCULATIONAHA.106.682450277119617485576Search in Google Scholar

39. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3(3):e1765.10.1371/journal.pone.0001765225841618335040Search in Google Scholar

40. Kaushik SV, Plaisance EP, Kim T, Huang EY, Mahurin AJ, Grandjean PW, et al. Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes Metab Res Rev. 2009;25(5):427-34.10.1002/dmrr.96719405044Search in Google Scholar

41. Goustin AS, Abou-Samra AB. The “thrifty” gene encoding Ahsg/Fetuin-A meets the insulin receptor: insights into the mechanism of insulin resistance. Cell Signalling. 2011;23(6):980-90.10.1016/j.cellsig.2010.11.00321087662Search in Google Scholar

42. Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010; 95(11):4877-81.10.1210/jc.2010-014820660040Search in Google Scholar

43. Alvarez-Llamas G, Szalowska E, de Vries MP, Weening D, Landman K, Hoek A, et al. Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics. 2007; 6(4):589-600.10.1074/mcp.M600265-MCP20017255083Search in Google Scholar

44. Roca-Rivada A, Al-Massadi O, Castelao C, Senín LL, Alonso J, Seoane LM, et al. Muscle tissue as an endocrine organ: comparative secretome profiling of slow-oxidative and fast-glycolytic rat muscle explants and its variation with exercise. JProteomics. 2012;75(17):5414-25.10.1016/j.jprot.2012.06.03722800642Search in Google Scholar

45. Perez-Sotelo D, Roca-Rivada A, Larrosa-Garcia M, Castelao C, Baamonde I, Baltar J, et al. Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity. Endocrine. 2017;55(2):435-46.10.1007/s12020-016-1132-127738888Search in Google Scholar

46. Pal D, Dasgupta S, Kundu R, Maitra S, Dias G, Mukhopadhyay S, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18(8):1279-85.10.1038/nm.285122842477Search in Google Scholar

47. Weikert C, Stefan N, Schultze MB, Pischon T, Berger K, Joost HG, et al. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008;118(24):2555-62.10.1161/CIRCULATIONAHA.108.81441819029462Search in Google Scholar

48. Laughlin G A, Cummins KM, Wassel CL, Daniels LB, Ix JH. The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am Coll Cardiol. 2012;59(19):1688-96.10.1016/j.jacc.2012.01.038334512722554599Search in Google Scholar

49. Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, Lee E, et al. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf). 2007;66(2):246-50.10.1111/j.1365-2265.2006.02716.x17223995Search in Google Scholar

50. Mukhopadhyay S, Mondal SA, Kumar M, Dutta D. Proinflammatory and antiinflammatory attributes of fetuin-a: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr Pract. 2014;20(12):1345–51.10.4158/EP14421.RA25370330Search in Google Scholar

51. Bilgir O, Kebapcilar L, Bilgir F, Bozkaya G, Yildiz Y, Pinar P, et al. Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern Med. 2010;49(13):1281-5.10.2169/internalmedicine.49.322320606360Search in Google Scholar

52. Ix JH, Katz R, de Boer IH, Kestenbaum BR, Peralta CA, Jenny NS, et al. Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the Multi-Ethnic Study of Atherosclerosis. Clin Chem. 2012;58(5):887-95.10.1373/clinchem.2011.17772522377528Search in Google Scholar

53. Sun ZL, Xie QY, Guo GL, Ma K, Huang YY. Serum fetuin-A levels in patients with cardiovascular disease: a meta-analysis. BioMed Research International. 2014;2014: 691540.10.1155/2014/691540421669125386562Search in Google Scholar

54. Laugsand LE, Ix JH, Bartz TM, Djousse L, Kizer JR, Tracy RP, et al. Fetuin-A and risk of coronary heart disease: a Mendelian randomization analysis and a pooled analysis of AHSG genetic variants in 7 prospective studies. Atherosclerosis. 2015;243(1):44-52.10.1016/j.atherosclerosis.2015.08.031460962126343871Search in Google Scholar

55. Sun Q, Jimenez MC, Townsend MK, Rimm EB, Manson JE, Albert CM, et al. Plasma levels of fetuin-A and risk of coronary heart disease in US women: the Nurses’ Health Study. J Am Heart Assoc. 2014;24(3):e000939.10.1161/JAHA.114.000939430909724963103Search in Google Scholar

56. Roos M, Oikonomou D, von Eynatten M, Luppa PB, Heemann U, Lutz J, et al. Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol. 2010;9:48.10.1186/1475-2840-9-48294971220822519Search in Google Scholar

57. Sezer S, Uçar F, Ulusoy EK, Erdogan S, Bilen S, Züngün C, et al. Serum amyloid A, fetuin-A, and pentraxin-3 levels in patients with ischemic stroke: novel prognostic biomarkers?. Turk J Med Sci. 2014;44(1):16-23.10.3906/sag-1211-9025558553Search in Google Scholar

58. Weikert C, Berger K, Heidemann C, Bergmann MM, Hoffmann K, Klipstein-Grobusch K, et al. Joint effects of risk factors for stroke and transient ischemic attack in a German population: the EPIC Potsdam Study. J Neurol. 2007;254(3):315-21.10.1007/s00415-006-0358-x17345050Search in Google Scholar

59. Wang YJ, Gong ZQ, Bi XM, Li YL. Correlation of plasma soluble cluster of differentiation 40 ligand, alpha fetoprotein A, and pregnancy-associated plasma protein A with carotid plaque in patients with ischemic stroke. Genet Mol Res. 2015;14(3):8091-9.10.4238/2015.July.17.1826214492Search in Google Scholar

60. Jiménez MC, Sun Q, Schürks M, Hu FB, Manson JE, Rexrode KM. Circulating fetuin-A and risk of ischemic stroke in women. Clin Chem. 2014;60(1):165-73.10.1373/clinchem.2013.212597397164424170613Search in Google Scholar

61. Wang H, Li W, Zhu S, Li J, D’Amore J, Ward MF, et al. Peripheral administration of fetuin-A attenuates early cerebral ischemic injury in rats. J Cereb Blood Flow Metab. 2010;30(3):493-504.10.1038/jcbfm.2009.247286073819953099Search in Google Scholar

62. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HE. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434-8.10.1210/jc.85.7.2434Search in Google Scholar

63. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1-13.10.2147/CLEP.S37559Search in Google Scholar

64. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):671-83.10.1016/j.bpobgyn.2004.05.00115380140Search in Google Scholar

65. Dunaif A Insulin resistance and the polycystic ovarysyndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800.10.1210/edrv.18.6.0318Search in Google Scholar

66. Enli Y, Fenkci SM, Fenkci V, Oztekin O. Serum fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol. 2013;29(12):1036-9.10.3109/09513590.2013.82944223961784Search in Google Scholar

67. Hasan AL-Aboudy NF, Hussain AL-Ani NK, Reda AlKawaz UM. The effect of different ovarian stimulation protocols on multifunctional fetuin_A concentration in the serum and follicular fluid of women with PCOS undergoing ICSI/IVF. Int. J. of Adv. Res. 2017;5(9):1012-9.10.21474/IJAR01/5418Search in Google Scholar

68. Okohue JE, Onuh SO, Ikimalo JI. Comparison of IVF/ICSI outcome in patients with polycystic ovarian syndrome or tubal factor infertility. Niger J Clin Pract. 2013;16(2):207-10.10.4103/1119-3077.11016423563463Search in Google Scholar

69. Farhan S, Handisurya A, Todoric J, Tura A, Pacini G, Wagner O, et al. Fetuin-A characteristics during and after pregnancy: result from a case control pilot study. Int J Endocrinol. 2012;896736.10.1155/2012/896736332127922536236Search in Google Scholar

70. Kalabay L, Cseh K, Pajor A, Baranyi E, Csákány GM, Melczer Z, et al. Correlation of maternal serum fetuin/alpha2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. Eur J Endocrinol. 2002;147(2):243-8.10.1530/eje.0.147024312153747Search in Google Scholar

71. Abali R, Celik C, Tasdemir N, Guzel S, Alpsoy S, Yuksel A, et al. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A concentration and caroid intima-media thickness in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;169(1):45-9.10.1016/j.ejogrb.2013.01.02323433744Search in Google Scholar

72. Gulhan I, Bozkaya G, Ozetkin D, Uyar I, Kebapsilar AG, Pamuk B. Serum fetuin-A levels in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2012;286(6):1473-6.10.1007/s00404-012-2494-022865037Search in Google Scholar